- GHK-Cu carries its strongest human record in topical cosmetic dermatology, where study populations skew heavily female, so women are relatively well represented in that narrow slice of the research.
- No indexed studies of GHK-Cu have analyzed hair or skin outcomes across menstrual cycle phase, and its topical safety in pregnancy is not established.
- Evidence for systemic or injected GHK-Cu is far weaker than the topical record and remains largely preclinical, so claims that travel from a cosmetic serum to an injectable are unsupported.
Hair-loss research has a reputation for male subjects, and much of the follicle-signaling literature earns it. The interesting exception is the copper-peptide corner, where the compound most often named for hair, GHK-Cu, happens to carry its best human evidence in cosmetic dermatology, a field whose study populations lean heavily female. That is a genuine data advantage, but it is narrow, and understanding exactly how narrow is the point of an evidence review written for women.
What GHK-Cu actually is
GHK-Cu is a naturally occurring copper-binding tripeptide, glycyl-L-histidyl-L-lysine complexed with a copper(II) ion, found endogenously in human plasma. In preclinical and in-vitro systems it has been studied for its role in copper transport and for its association with collagen and elastin gene expression, fibroblast activity, glycosaminoglycan synthesis, and matrix-remodeling signaling. Those are tissue-remodeling pathways that overlap with the biology of the dermal environment around the follicle, which is part of why it enters the hair conversation at all.
Where the female data is, and where it isn't
Because cosmetic-dermatology trials skew female, women are comparatively well represented in the topical GHK-Cu record. That is the good news, stated honestly. The limits are just as important. Very few of those studies reported sex-stratified outcomes, so the female representation is a property of who enrolled rather than a set of results analyzed by sex. And the studies did not analyze cycle phase, so how the compound behaves across the menstrual cycle is simply unstudied.
- Menstrual cycle interactions: unstudied. Cosmetic skin studies did not analyze cycle phase.
- Perimenopause and menopause: several dermatology studies enrolled peri- and postmenopausal women for skin-aging endpoints.
- Sex differences: no clear evidence. Populations skew female, but very few studies reported outcomes stratified by sex.
- Hormonal interactions: no interaction data has been indexed.
- Pregnancy and lactation: topical cosmetic safety in pregnancy is not established, and systemic use has no data.
The comparatively strong human record for GHK-Cu sits with topical cosmetic formulations. Evidence for systemic or injected use is far weaker and largely preclinical. A finding in a face serum study is not a finding about an injection, and the two should never be read as the same claim.
How to read hair-growth claims
Most consumer hair claims for copper peptides describe association with collagen and matrix signaling and then imply a downstream follicle result. In the research literature GHK-Cu has been studied for those signaling relationships, but that is mechanism, not a demonstrated human hair outcome, and it is not framed here as one. For female-pattern hair loss specifically, no controlled trials of GHK-Cu with sex-stratified endpoints have been indexed, so the honest position is that the mechanism is characterized while the female-specific hair result is not.
That distinction, mechanism present, female clinical result absent, is the recurring shape of this catalog. GHK-Cu is one of the better cases because its cosmetic research at least enrolled women in numbers. If you want the full breakdown of its evidence states and grade, see the GHK-Cu profile, which tracks exactly how many of the underlying studies included female subjects.